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ABSTRACT
Introduction: Text message interventions have been
shown to be effective in prevention and management
of several non-communicable disease risk factors.
However, the extent to which their effects might vary in
different participants and settings is uncertain. We aim
to conduct a systematic review and individual
participant data (IPD) meta-analysis of randomised
clinical trials examining text message interventions
aimed to prevent cardiovascular diseases (CVD)
through modification of cardiovascular risk factors
(CVRFs).
Methods and analysis: Systematic review and IPD
meta-analysis will be conducted according to Preferred
Reporting Items for Systematic review and Meta-
Analysis of IPD (PRISMA-IPD) guidelines. Electronic
database of published studies (MEDLINE, EMBASE,
PsycINFO and Cochrane Library) and international trial
registries will be searched to identify relevant
randomised clinical trials. Authors of studies meeting
the inclusion criteria will be invited to join the IPD
meta-analysis group and contribute study data to the
common database. The primary outcome will be the
difference between intervention and control groups in
blood pressure at 6-month follow-up. Key secondary
outcomes include effects on lipid parameters, body
mass index, smoking levels and self-reported quality of
life. If sufficient data is available, we will also analyse
blood pressure and other secondary outcomes at
12 months. IPD meta-analysis will be performed using
a one-step approach and modelling data
simultaneously while accounting for the clustering of
the participants within studies. This study will use the
existing data to assess the effectiveness of text
message-based interventions on CVRFs, the
consistency of any effects by participant subgroups
and across different healthcare settings.
Ethics and dissemination: Ethical approval was
obtained for the individual studies by the trial
investigators from relevant local ethics committees.
This study will include anonymised data for secondary
analysis and investigators will be asked to check that
this is consistent with their existing approvals. Results
will be disseminated via scientific forums including
peer-reviewed publications and presentations at
international conferences.
Trial registration number: CRD42016033236.
INTRODUCTION
Non-communicable diseases (NCD), includ-
ing cardiovascular disease (CVD) is the
leading cause of death and disability in most
parts of the world. During recent decades,
the prevalence of CVD has increased in
many low and middle income countries,1
Strengths and limitations of this study
▪ This study uses a systematic approach to identify
all potential trials examining the effectiveness of
text messaging intervention for cardiovascular
disease (CVD) prevention.
▪ The study will gather all available individual par-
ticipant data (IPD) from previous trials for an
IPD meta-analysis, which offers superior and
more powerful analysis then convenient
meta-analysis alone.
▪ The study will have sufficient data to compare
the effects of text messaging across different
subgroups.
▪ The Text2PreventCVD collaboration network
would enable consensus from all the trialists to
promote appropriate use of text messaging for
CVD prevention.
▪ The resources, time and strong international col-
laboration required for such data analysis is a
limitation.
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causing signiﬁcant premature mortality and morbidity.
However, existing evidence indicates that a substantial
proportion of the burden of CVD is avoidable through
targeting cardiovascular risk factors (CVRFs) including
smoking, high blood pressure (BP), lipids, diabetes,
overweight and obesity and sedentary behaviours. CVD
is a costly condition and has serious impact on indivi-
duals, families, society, health systems and nations as a
whole. The WHO estimated that over three-quarters of
all CVD mortality takes place in developing countries,
which could be prevented with adequate lifestyle modiﬁ-
cation.2 However, identifying low-cost, scalable and
effective strategies to prevent CVD remains a major chal-
lenge in developed and developing countries.
In recent years, mobile health (mHealth) has gained
increasing momentum with the potential to transform
how we deliver healthcare, through scalability, affordabil-
ity and personalisation.3 Furthermore many people
across all income groups own mobile phones, particu-
larly in low-income countries where mobile phone usage
is generally higher than ﬁxed-line usage,4 and as such
mHealth interventions has the potential for substantial
population impact. Using brief text messages to deliver
CVD prevention support programmes via mobile phones
is a potential exemplar.5
Several trials are currently being conducted of text
message-based interventions in CVD prevention and
management in different regions of the world.6–9 Most
of these trials do not have sufﬁcient power and are not
sufﬁciently large to examine generalisability across set-
tings and patient subgroups, nor effects on longer-term
clinical outcomes. While systematic review and
meta-analysis can help establish generalisability and
overall effectiveness, individual participant data (IPD)
meta-analyses enables examination of common sub-
group effects, for example by gender, age or education.
In addition, a more detailed examination of the compo-
nents of text message-based programmes is needed to
inform translation of this research to practice. The
details of intervention may not be published in a com-
parable way and therefore involving study investigators
of the original studies will enable a more detailed com-
parison of text message-based intervention components.
This protocol aims to describe the steps that we plan
to undertake to synthesise the existing data on text
message-based interventions for CVD prevention using
systematic review and IPD meta-analysis. The ﬁndings of
this research have important implications for developing
prevention programmes for CVDs in different contexts.
Objectives
Our overall objective is to establish a formal collabor-
ation among several international groups conducting
clinical trials of text message-based interventions in CVD
prevention and facilitate the next generation of clinical
trials in this area. The speciﬁc objectives are to:
1. Conduct a systematic review to identify relevant
research teams and studies;
2. To invite teams to contribute data to conduct IPD
meta-analyses;
3. To use IPD:
A. To examine the effect of text message-based inter-
ventions on outcome measures;
B. To investigate if the effects of text messages vary
by patient characteristics (eg, sex, age group,
socioeconomic group);
C. To examine if the effect of text message-based
interventions vary by intervention characteristics
(eg, personalisation, frequency);
D. To compare and contrast content characteristics
of intervention programmes.
An important aim will be to examine the variation in
effects of text-messaging interventions by key subgroups.
There has been variation in the proportion of men and
women recruited to some studies, and while this may be
the nature of the disease conditions, it is unclear
whether texting interventions are similarly effective in
men and women. There is also the perception that
there may be variation in use of mobile phones and
mobile technologies in younger and older people, and
variation by socioeconomic group. A recent trial using
mobile phone text messages for improving adherence to
retroviral medication showed that effects varied by edu-
cation, gender, the timing of text messaging and inter-
activity.10 Women, higher education and weekly text
messages had signiﬁcant positive interactions with text
messaging. A study by Lester and colleagues reported
from subgroup analysis that text messaging for antiretro-
viral treatment adherence worked better in males parti-
cipants living in urban areas, and those who own a
mobile phone.11
Another key aim is whether there is variation in effect-
iveness by intervention characteristics, speciﬁcally if
more frequent messaging is beneﬁcial, and whether
intervention programmes that use personalisation are
more effective.
METHODS
Systematic review and IPD meta-analysis will be
performed according to Preferred Reporting Items for
Systematic review and Meta-Analysis of IPD
(PRISMA-IPD) guidelines.12
Inclusion criteria for selected studies
Studies will be included if they meet the following inclu-
sion criteria:
▸ Study type: Randomised controlled trials (RCTs) of
mobile phone Short Message Service (SMS) or text
message intervention with a follow-up period of at
least 6 months and a minimum 70% of completed
follow-up of patients.
▸ Study population: Participants aged 18 years and
older, both men and women will be included. There
will be no limits on study participants in terms of eth-
nicity, religion, occupation, income and morbidities
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such as, presenting with history of myocardial infarc-
tion or chronic heart diseases, CVRFs (diabetes,
hypertension), cerebrovascular diseases or peripheral
vascular diseases.
▸ Study focus: Only studies focusing on CVD primary
and secondary prevention will be included.
▸ Intervention: Studies that involve the delivery of brief
automated text messages (SMS) via a mobile phone
device as the core component of the intervention.
The intervention should be using at least any two of
the behavioural techniques/strategies to achieve
behaviour change, eg: education and reinforcement
content. For example, interventions that focus only
on medication reminders will be excluded. The
mode of text message delivery can be a standard SMS
or messaging apps like WhatsApp.13
▸ Sample size: A minimum total sample size of 30 partici-
pants. We have chosen to have a lower limit for sample
size as we perceive the sample size to be a surrogate
marker of study quality. Smaller sample size studies are
more likely to be demonstration projects with less
emphasis on rigour in recruitment and randomisation.
▸ Study setting: There will be no limits on study setting,
that is, primary, secondary or tertiary care, commu-
nity based or at patients’ home.
▸ Comparator: Participants in the control group receiv-
ing standard-care (no messages or some form of
control message).
▸ Language: Studies published in any language will be
considered and translations will be sought, if required.
▸ Publication time: Studies published after 1990 will be
considered. Studies prior to 1990 will not be included
because mobile phones were mostly non-existent
prior to this date (http://news.bbc.co.uk/2/hi/uk_
news/2538083.stm).
Exclusion criteria:
Studies that included only clinic appointment reminders
will be excluded. Web-based interventions without the
use of mobile phones/SMS are outside the scope of this
review. Also, studies targeted towards healthcare provi-
ders or other stakeholders rather than patients or consu-
mers of healthcare services, and all studies where audio
intervention or voice message is primary component will
be excluded.
The criteria for including studies in the review can be
summarised in the following PICOS format:
Population—Individuals (adults) of any demographic
background;
Intervention—Mobile phone SMS or texting services;
Comparator—Intervention versus usual care;
Outcomes—Any two outcomes related to the prevention
of CVD as follows: changes in BP, blood lipid levels,
blood glucose, physical activity and diet;
Setting—Randomised controlled studies conducted in
any setting (high, middle and low income countries
according to United Nations (UN) Human
Development (HD) index 2015; hospital or community
based).
Identification of studies
Potentially eligible studies will be identiﬁed prospectively
through using a range of methods, including extensive
search of electronic database, trial registers, manual
search of journals and the grey literature.
1. Electronic database: The following electronic data-
bases will be searched: MEDLINE, the Cochrane
Library, including Cochrane Central Register of
Controlled Trials (CENTRAL); Cochrane Database of
Abstracts of Reviews of Effects (DARE); the Cochrane
Consumers and Communication Review Group
Specialised Register; the EMBASE and PsycINFO
(Ovid).
2. Trial registers: Ongoing, recently completed and
unpublished clinical trials meeting the inclusion cri-
teria described above will be identiﬁed from the fol-
lowing registers: for example, clinicaltrial.gov, The
Australian New Zealand Clinical Trials Registry
(ANZCTR), Pan-African and WHO-International
Clinical Trials Registry Platform (ICTRP).
3. Other sources: In addition, the websites of relevant
public and private organisations will be searched for
publications in connection with the review’s objec-
tives. The list of such organisations includes, but is
not limited to: WHO; the World Bank; World
Economic Forum; and NCD Alliance. We will also
review the grey literature including, Google Scholar,
New York Academy of Medicine Grey Literature
Report and any other relevant sources.
Screening and study selection
In order to conduct a comprehensive search, the follow-
ing Medical Subject Headings (MeSH) search terms will
be used: (1) intervention (text messaging, text messages,
SMS, text message mobile phone, cellular phone,
texting, SMS); (2) CVD (BP, hypertension, lipids, choles-
terol, myocardial infarction, stroke, heart failure,
arrhythmias, diabetes and obesity) and (3) study design
(RCT). Advanced search, allowing for explosion search,
searching keywords or browsing additional similar terms
will be used whenever feasible.
Search results across electronic databases will be
merged using reference manager software EndNote
(Thomson Reuters Corporation, New York, New York,
USA),14 and duplicate records of the same study will be
removed. Study selection will follow the process
described in Cochrane Handbook of Systematic Reviews
and PRISMA-IPD statements.12 Two researchers (SMSI
and KS) will independently screen titles and abstracts to
remove irrelevant studies to identify studies that are
meeting the inclusion criteria described above and
extract data. Any disagreements will be resolved by con-
sensus or in consultation with a third reviewer (CKC).
Reference lists of the selected articles and reviews will be
searched manually to identify additional relevant
studies. Consultation and contacts with experts in this
ﬁeld will be made to help identify relevant studies. The
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detailed search strategies are presented in online
supplementary appendix 1.
Study outcomes
In accordance with the study research objectives we will
perform IPD meta-analysis for the following outcomes
from eligible trials (table 1).
Data management
We will seek data for all patients at all timepoints and
grouped for the purpose of analysis: short term (6–12
months), medium term (13–24 months) and long term
(>24 months). We will also seek individual key baseline
patient demographic, anthropometric and clinical data
(including age, gender, education, marital status, occu-
pation, income, weight, height, systolic and diastolic BP,
pulse rate, waist and hip circumference and race/ethni-
city). For BP, we will request all the available BP data
and take the mean of two values. Where three BP read-
ings are available, we will discard the ﬁrst reading and
take the mean of the remaining two readings. Details of
self-reported comorbidities and medication use will be
collected. Where available, we will seek from investiga-
tors details at an individual participant level of the
amount of physical activity/physical ﬁtness and diet
among other variables. If there is sufﬁcient data, we will
also report BP and other secondary outcome measures
at 12 months. Information will be collected using a stan-
dardised questionnaire from all originator investigators
and in-depth interview with investigators that is, qualita-
tive methodology to better understand the process of
development of the text messages, and how the interven-
tion worked. The data collection form is annexed (see
online supplementary appendix 2). We plan to compare
the different behaviour technique taxonomy of the text
message intervention in a separate paper using
Michie’s15 behaviour change techniques used in
interventions.
IPD meta-analysis
The principal investigators of the selected trials meeting
the inclusion criteria will be invited by email to join the
international consortium of Text2PreventCVD Trial
Collaborators Group. Reminders will be sent after a
week to non-responders, followed by approaching other
investigators by email, phone calls, fax and other com-
munication channels. Investigators will be requested to
share their anonymised data after obtaining a signed
agreement, preferably electronically using encrypted
ﬁles and other secure data transfer technologies using
standardised data collection forms. Data transfer will be
via an encrypted data ﬁle sent by email or using a
Table 1 Study outcome, measurements and plans to unify the data
Study
outcomes Variables Measurements Plans to unify
Primary The difference between
intervention and control groups in
SBP at 6-month follow-up
mm Hg Mean SBP
Secondary DBP at 6-month follow-up mm Hg Mean DBP
BMI kg/m2 Mean BMI
WC cm Mean WC
HC cm Mean HC
Smoking tobacco Current or within the past 6 months Proportion of current/
past smokers
Physical activity Sufficiently active/METS Proportion of sufficiently
active/mean METS
Diet Number of fruits and vegetables serving per
week
Proportion
QoL Score Mean score
HbA1c Percentage Mean HbA1c
Lipid parameters (LDL
cholesterol)
mg/dL Mean change
CV events Angina, myocardial infarction, stroke,
arrhythmias, coronary heart diseases, valvular
heart diseases, cardiomyopathy, etc
Number of events
CV composite score CV risk factors Number of CV risk
factors controlled with
the intervention
SBP and DBP at 12 months mm Hg Mean SBP and mean
DBP
BMI, body mass index; CV, cardiovascular; DBP, diastolic blood pressure; HbA1c, glycated haemoglobin; HC, hip circumference; LDL,
low-density lipoprotein; METS, Metabolic Equivalent of Task; QoL, quality of life; SBP, systolic blood pressure; WC, waist circumference.
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password-protected drop box facility created for the
project. Data will be stored in a secure computer server
managed by the secretariat. Data collection, collation
and analysis will be coordinated by the project secretar-
iat based at the cardiovascular division of the George
Institute for Global Health, Sydney, Australia.
Data merging and quality assurance
Data merging will be performed by a statistician at the
George Institute for Global Health. Deﬁnitions of vari-
ables will be carefully checked to ensure that they are
identical or whether recoding is required, this is care-
fully documented in a detailed analysis plan. The
merged data set will be carefully checked. Data from
each study will be evaluated and compared with the
available publication(s). Each data set will be checked
for the range of included variables to make sure that all
values are reasonable and to identify missing values
against the original publication. Attempt will be made to
replicate results reported in the original publication,
including baseline characteristics and outcome data at
each available follow-up period, by reproducing the stat-
istical methods as reported by the study authors. Any dis-
crepancies or missing information between the results
and those presented in each original publication will be
discussed and clariﬁed with the original study authors or
principal investigators. Once data checks are complete
and satisfactory, individual study data sets will be com-
bined to form a new master data set with a variable
added to indicate the original study. Copies of the
master data set will be maintained by the project secre-
tariat at The George Institute (TGI). Data from individ-
ual datasets will remain the property of the study
collaborators who have provided IPD. The study proto-
col will be reported as per PRISMA Protocols
(PRISMA-P) 2015 checklist: recommended items to
address in a systematic review protocol16 (see online
supplementary appendix 3).
Statistical analyses
Data analyses will be conducted in accord with contem-
porary recommendations for IPD meta-analyses.17–19
Data analysis will be performed using Stata V.12/SPSS
V.20 (IBM Corporation, USA).
Descriptive and exploratory analyses will be used to
identify and display differences in baseline character-
istics between the types of patients enrolled in the trials,
in particular, statistical comparisons of baseline means
(using Student’s t-tests) and prevalence’s (using χ2 tests)
between different groups of patients. The rationale for
performing these initial descriptive analyses is because
an understanding of how patients differ between trials
that might aid the interpretation of any apparent
between-trial treatment differences that may arise.
Study-level and patient-level characteristics of included
studies will be presented. An interim meta-analysis of
the systematic review is planned. This will allow
considering the results of the studies which did not
agree to share data for the IPD.
Analysis of primary end point: Our approach to the
analysis of the primary outcome of the differences
between intervention and control groups in systolic BP
at 6 months will be by intention to treat. There are two
methods of undertaking IPD meta-analysis: (1) using
IPD to derive aggregate data for each study, followed by
meta-analysis of the aggregate data (‘two-step IPD
meta-analysis’) and (2) analysis of individual patient
data using a mixed model and accounting for clustering
of patients within studies (‘one-step IPD meta-analysis’).
In this project we will use one-step IPD meta-analysis,
which is the most logistically demanding, but does allow
for the most sophisticated modelling of covariates and
has the best performance in terms of power.17
All randomised patients with outcome data will be
included in the analysis. Time-to-event end points will
be analysed using appropriate models which accommo-
date censored data (eg, Cox proportional hazards
models). Continuous outcomes will be analysed using
linear models with adjustments for baseline values.
Appropriate models will be used, with a ﬁxed effect on
individual study and patient-level covariates, as well as a
comparison of models with a ﬁxed effect on interven-
tion and random effects on intervention across trials.
Analysis of secondary endpoints: Changes in second-
ary outcome will be measured by one-stage or appropri-
ate statistical method, as above. Heterogeneity will be
assessed using the I2 statistic from the two-stage
meta-analysis and in the unlikely event it is very low or
zero we will run a sensitivity analysis using standard
general linear models (ﬁxed effect).
Adjusted and subgroup analyses: This will be per-
formed based on key baseline characteristics. Subgroup
analyses will be displayed using forest plots. Any modiﬁ-
cation of treatment effects across predeﬁned patient sub-
groups (ie, age, gender, socioeconomic group, ethnicity,
etc), duration of SMS intervention20 and trial geograph-
ical locality will be assessed by examining the signiﬁ-
cance of the subgroup by intervention interaction term
within the model. The importance of the number of
SMSs will be assessed by ﬁtting the duration of interven-
tion as a continuous variable and examining the inter-
action with intervention. Mediation analysis will be
conducted to examine the association between changes
in BP and health-related quality of life and clinical
events.19 21 22
Sensitivity analyses: We will undertake a number of
sensitivity analyses to test the robustness of conclusions.
These will include: exclusion of studies from the primar-
ily identiﬁed review that have a high risk of bias and
trials with an overall SMS duration of <24 weeks. We will
assess publication bias in this IPD meta-analysis in
accord with the recommended methods.23 Before per-
forming the pooled analysis, we will assess the hetero-
geneity across studies using either the Cochrane Q
statistic or the I2 statistic.
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When IPD cannot be obtained, the impact on
meta-analysis conclusions will be investigated by includ-
ing the aggregate data from those studies where IPD is
unavailable. Where the inclusion of studies lacking IPD
seem to have an important statistical or clinical impact,
it may be helpful to compare the characteristics of the
studies with IPD and those without to see whether there
are key differences (eg, quality, length of follow-up, stat-
istical methods). We will also assess funnel plot asym-
metry (with and without studies using IPD) and perform
Egger’s regression test (for small study effect or publica-
tion bias). Additional research questions and other pre-
speciﬁed analyses will be performed as determined and
agreed by the group members.
Analysis of other efﬁcacy endpoints: To compare and
contrast content characteristics of intervention pro-
grammes, we will conduct a separate review of the devel-
opment of the various text-based interventions and a
comparison of subsequent content characteristics and
process evaluation. We will use a combination of quantita-
tive and qualitative methodology to provide comparative
data on the characteristics of intervention programmes.
Adverse events: Any adverse event reported in the
trials will be extracted and analysed with number, per-
centage and difference between groups at the end of
the trial.
Project management, coordination
The Text2PreventCVD Trial Collaborator Group refers
to the core team of researchers who will oversee the stra-
tegic direction of the protocol; the ‘Text2PreventCVD’
refers to all those linked to the project and includes trial
teams who have signed institutional agreements to
provide data sets for the study.
Project secretariat
The Text2PreventCVD secretariat based at the cardiovas-
cular division of the George Institute for Global Health
will perform the following roles: act as a liaison between
members of the collaborative group and agree to the
research questions addressed by the collaboration and
develop the initial protocol. Members of the collabora-
tive group will be given opportunities to participate in
decision-making regarding the study design and analyses
and will have opportunities to network and identify
future Text2Prevent research questions suitable for ana-
lysis. The secretariat will develop mechanisms for com-
munication and input on methodological issues, agree
to the data collection proforma; secure data handling;
review the publication strategy for the collaboration;
ensure that data are only used, and any additional
research (including updating of the combined data sets
with emerging evidence) only proceeds, following con-
sultation and agreement with the group members; and
lead future applications for research funding on behalf
of collaborative group projects.
Data ownership and confidentiality
Participants in the individual trials have previously con-
sented to participation in their respective trial. Given
that the analyses proposed are simply an extension of
the core analysis of the constituent trials, we do not
anticipate that additional ethical permission will be
required.
All trial data will be regarded as strictly conﬁdential,
and will not be provided to any third party without the
prior written permission of the owners of the data.
However, if appropriate, and agreed by the members,
the same data set may be held elsewhere, and if so, strict
conﬁdentiality and data security at each data repository
will be maintained. The secretariat will be responsible
for collating and checking the data (in 1 location until
complete, then will ensure that the ﬁnal locked analysis
data set is held in each data repository).
We will ensure that datasets shared as part of the
project include no patient identiﬁable information
(such as names and addresses), that all data storage is in
accordance with the regulations governing research at
TGI, and will obtain a signed data sharing agreement
for 7 years with all authors to outline procedures for the
transmission, storage, analysis and dissemination. The
collaborators remain the custodians of their own data
and retain the right to withdraw their data from the ana-
lysis at any time.
Publication policy
Recommendations will be followed for authorship in IPD
analyses and multicentre studies.24 25 Where possible, we
will follow the policy of members of the collaborative
group being listed as authors and names of other partici-
pating collaborators listed in the acknowledgements. All
collaborators will be expected to participate fully in
manuscript preparation and editing, and will be expected
to consult with, and collate comments from, colleagues
from the trials they represent. Requirements for author-
ship will follow those of the International Committee of
Medical Journal Editors (http://www.icmje.org). A
primary publication of the results of this review will be
prepared by the secretariat. This and all other manu-
script drafts will be circulated to the members of the
group for comments, revision and approval.
Timeline and funding
All currently identiﬁed trials are fully or partially funded
and have completed recruiting. We will formally invite
all collaborators to an initial face-to-face meeting with
the aim to prospectively document the protocol. We will
seek funds to support collaborative meetings, statistical
analyses and a partial support for a postdoctoral
research fellow/statistician. The secretariat will prepare
grant applications as appropriate for support and submit
in the name of the group as a whole, including
members of the group as co-applicants.
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Ethics and dissemination
Ethical approval was obtained for the individual studies
by the trial investigators from relevant local ethics com-
mittees. This study will include anonymised or
de-identiﬁed data for secondary analysis and investiga-
tors will be asked to check that this is consistent with
their existing approvals. Study data will not be used for
any other purpose without the permission of collabora-
tors. Members of the collaborative groups are listed at
the end of this protocol. Results of the study will be dis-
seminated in peer-reviewed publications and by inter-
national conference presentations.
DISCUSSION
Robust data on the effectiveness of mobile phone-based
text messages intervention for CVD prevention is mostly
not available. The vast majority of previous studies have
been limited in sample size and single centre. This sys-
tematic review and IPD meta-analysis will provide an
excellent platform for the next generation trials that are
needed, testing further improvements in the interven-
tion space and recruiting many times more participants
internationally.
Strengthening CVD prevention is essential to reduce
many cardiovascular outcome events and their complica-
tions including premature death and disability, which
would ultimately lead to reduce healthcare costs, increase
economic productivity and improve quality of life.26 This
collaboration provides an excellent opportunity to deter-
mine the consistency or otherwise of beneﬁts of such
interventions across varying healthcare systems, countries
and whether other contextual factors modify the effects.
Combining the data from these trials will offer insight
into the overall effectiveness of text message-based
support programmes. This approach has been used by
several international collaborative groups including the
Asia Paciﬁc Cohort Studies Collaboration, the Single Pill
to Avert Cardiovascular Events (SPACE) collaboration,27
the Blood Pressure Lowering Treatment Trialists’ colla-
borations led from the George Institute.28 A formal col-
laboration also has the additional beneﬁts of enabling
systematically specifying components of the intervention
programmes to facilitate reproduction and comparison,
and providing further details about the context in which
the programmes have been delivered to inform imple-
mentation. Investigators will also be invited to participate
in a face-to-face conference meeting at the secretariat in
Sydney for obtaining data and clariﬁcation. If any investi-
gator or team fails to attend the face-to-face programme,
they will be invited to join the meeting remotely using
teleconference. Further efforts include informing net-
works of the proposed IPD and approaching investigators
known to conduct similar studies to join the network as a
part of ongoing programme.
The main beneﬁts of an IPD meta-analysis include the
ability to address some important outstanding questions,
suggest new hypotheses and help identify future research
questions. IPD meta-analysis offers superior and more
powerful analysis then traditional meta-analysis. In add-
ition to further increasing the precision of information on
time to treatment, many outstanding questions about SMS
intervention for CVD prevention will be informed by this
collaborative meta-analysis. Robust data from an updated
individual patient meta-analysis would provide the highest
level of evidence, but consensus from all the trialists would
be enormously helpful in promoting a substantial increase
in the appropriate use of text messaging for the preven-
tion of CVD. A limitation of this IPD meta-analysis is the
retrospective data analysis. In addition, the resources, time
and strong international collaboration required for such
data analysis is another limitation.
CONCLUSION
This systematic review and IPD meta-analysis of SMS
interventions will provide comprehensive evidence on
the effectiveness of text messaging for CVD prevention
in different settings and help to formulate CVD preven-
tion policies and programmes.
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